“…In line with this, neurobiological candidate endophenotypes of anxiety disorders, to be assessed by family-genetic studies, may inform about the stability of observed alterations and could potentially serve as risk signatures (Bas-Hoogendam et al, 2016;Bas-Hoogendam, Harrewijn, et al, 2018;Bas-Hoogendam, van Steenbergen, van der Wee, & Westenberg, 2020;Bearden & Freimer, 2006;Beauchaine & Constantino, 2017;Glahn et al, 2012;Glahn, Thompson, & Blangero, 2007;Hasler, Drevets, Gould, Gottesman, & Manji, 2006;Lenzenweger, 2013;Miller & Rockstroh, 2013) (Etkin, 2019). Prospectively planned research would ensure that clinical data as well as confounding variables are carefully collated, and longitudinal designs would allow more detailed investigation of the mechanisms underlying anxiety disorders as well as of the impact of interventions (Gloster et al, 2009;Heinig et al, 2017;Månsson et al, 2016;Phan et al, 2013;Schwarzmeier et al, 2019;Steiger et al, 2017;Talati et al, 2015;Yang et al, 2019); cf. the accomplishments by the Alzheimer's Disease Neuroimaging Initiative (ADNI), an ongoing, longitudinal, multicenter study aimed at developing clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease using standardized methods (Mueller et al, 2005;Weiner et al, 2013).…”